Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 5:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 7,746 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Up to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Lymphoma, Follicular
Interventions
Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 15 more
Conditions
B Cell, Acute Lymphoblastic Leukemia, Relapsed/Refractory
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Not applicable Interventional

Edwards EVOQUE Eos MISCEND Study

NCT02718001
Conditions
Mitral Valve Regurgitation (Degenerative or Functional)
Interventions
Edwards EVOQUE Eos Mitral Valve Replacement System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2033
U.S. locations
16
States / cities
Burlingame, California • Los Angeles, California • San Francisco, California + 13 more
Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
Interventions
AUTO CAR T cell therapy
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Conditions
L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
cytarabine, methotrexate, vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, imatinib mesylate, cyclophosphamide, etoposide, filgrastim, leucovorin calcium, asparaginase, therapeutic hydrocortisone
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Refractory Multiple Myeloma
Interventions
liposomal doxorubicin, bortezomib, dexamethasone, cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
130
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 94 more
Conditions
Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Dasatinib, Dexamethasone, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), Prednisone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia, Lymphoblastic, Acute, ALL, Childhood
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 40 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma,Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
16
States / cities
West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Magnetic Resonance Imaging, Obinutuzumab, Venetoclax
Procedure · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Long Beach, California + 4 more
Conditions
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Laboratory Biomarker Analysis, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Oprozomib, Lenalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Huntsville, Alabama • Burbank, California • Los Angeles, California + 11 more
Conditions
Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma
Interventions
Dexamethasone, Idasanutlin, Ixazomib Citrate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Duarte, California • Jacksonville, Florida • Atlanta, Georgia + 5 more
Conditions
Relapsed/Refractory Aggressive B-Cell Lymphoma
Interventions
cemiplimab, odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Conditions
Post-transplant Lymphoproliferative Disorder
Interventions
Rituximab, Acalabrutinib, CT scans
Drug · Diagnostic Test
Lead sponsor
Deepa Jagadeesh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts
Interventions
Dilanubicel, Cyclophosphamide, Fludarabine, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Laboratory Biomarker Analysis, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Multigated Acquisition Scan, Electrocardiography, Computed Tomography
Biological · Drug · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Interventions
Total skin electron beam therapy (TSEBT), Vorinostat
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Stanford, California • New Haven, Connecticut • Houston, Texas
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
monoclonal antibody SGN-30, placebo, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
Interventions
Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
30
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 24 more
Conditions
Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Lymphoma
Interventions
Non Interventional
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York